TickerFacts.

Silence Therapeutics plc (SLN): Capital Expenditures

Annual figures by period end, from SEC filings.

$55.0K
Year ended 2025-12-31
$3.0K
Trailing 12 months to 2026-06-30
-31.7%
3-year compound annual growth
$211.0K2022-12-31: $173.0K2023-12-31: $56.0K2024-12-31: $211.0K2025-12-31: $55.0K$55.0K
2022-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$55.0K-73.9%2026-03-05, From 2025-01-01
2024-12-31$211.0K+276.8%2026-03-05, From 2024-01-01
2023-12-31$56.0K-67.6%2025-02-27, From 2023-01-01
2022-12-31$173.0Kn/a2025-02-27, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Silence Therapeutics plc (SLN)2025-12-31$55.0K-73.9%
Yarrow Bioscience, Inc. (YARW)2025-12-31$0-100.0%
Quantum Cyber N.V. (QUCY)2025-12-31$1.2K-98.8%
PMGC Holdings Inc. (ELAB)2025-12-31$442.3Kn/m
Vaccinex, Inc. (VCNX)2024-12-31$22.0K-67.2%
Mereo BioPharma Group plc (MREO)2025-12-31$20.0Kn/a
BioXcel Therapeutics, Inc. (BTAIQ)2025-12-31$0n/a
Polomar Health Services, Inc. (PMHS)2024-12-31$90.9Kn/a
Lexaria Bioscience Corp. (LEXX)2025-08-31$24.6K-42.7%

Compare SLN, YARW, QUCY, ELAB side by side · Screen every company in Pharmaceutical Preparations ↗